Cite
HARVARD Citation
Benito, V. et al. (n.d.). 2022-RA-1689-ESGO Should immunotherapy be included as first-line adjuvant treatment in high-risk vulvar melanomas?. International journal of gynecological cancer. pp. A451-A452. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Benito, V. et al. (n.d.). 2022-RA-1689-ESGO Should immunotherapy be included as first-line adjuvant treatment in high-risk vulvar melanomas?. International journal of gynecological cancer. pp. A451-A452. [Online].